

## 2025 New Working Committee Studies

Working Committee	Study #	Study Title	Principal Investigators
Graft-versus-Host Disease	GV25-01	Abatacept versus post-transplantation cyclophosphamide as GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation for myeloid malignancies.	Sayeeff Mirza/ Joseph Pidala
Immunobiology	IB25-01	Haploidentical donor selection for patients with Aplastic Anemia: HLA and non-HLA factors.	Rohtesh Mehta/ Annalisa Ruggeri
Infection and Immune Reconstitution	IN25-01	Risk Stratification and Letermovir Prophylaxis Strategies for Cytomegalovirus in Hematopoietic Cell Transplantation: A Focus on Late CMV Infections, All-Cause Mortality, and Mismatched Donor-Recipient Serostatus	Roy Chemaly/ Marjorie Batista/ Justin Tossey/ Jeremy Sen/ Zainab Shahid/ Hemant Murthy
Leukemia	LK25-01	Comparison of FluFTBI and other myeloablative Conditioning Regimens for Haploidentical and mismatched unrelated Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide in Patients with Acute Leukemia.	Shukaib Arslan/ Monzr Al Malki
Leukemia	LK25-02	Myelodysplastic Neoplasms with Hypoplasia (MDS-h) or Fibrosis (MDS-f): Distinct Clinical Entities Compared to Other MDS Subtypes.	Arjun Law/ Sergio Rodriguez Rodriguez
Leukemia	LK25-03	Impact of Post-Transplant Cyclophosphamide Based GVHD prophylaxis on Outcomes in Patients with CMML Undergoing Allogeneic Stem Cell Transplant.	Yasmeen Berry/ Shatha Farhan/ Indumathy Varadarajan/ Karen Ballen
Lymphoma	LY25-01	Axi-cel vs. Liso-cel in Second line in DLBCL.	Agrima Mian/ Brian T. Hill/ Daniel Reef/ Natalie Grover
Lymphoma	LY25-02	Real-world Outcomes Following Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Older Patients with Large B Cell Lymphoma.	Mengyang Di/ Mazyar Shadman/ Supriya Gupta/ Veronika Bachanova/ Preetesh Jain/ Anath Lionel
Morbidity, Recovery and Survivorship	MRS25-01	Association of fludarabine exposure on car-t outcomes.	Karen Sweiss/ Sairah Ahmed

2025 New Working Committee Studies			
Working Committee	Study #	Study Title	Principal Investigators
Morbidity, Recovery and Survivorship	MRS25-02	CIBMTR Validation of the Transplant Conditioning Intensity (TCI) Classification System in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome receiving GVHD prophylaxis with or without Post-Transplant Cyclophosphamide.	Antonio M. Jimenez Jimenez/ Brian C. Shaffer/ Clayton Jackson/ Lori Muffly
Morbidity, Recovery and Survivorship	MRS25-03	Real World Experience of Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC HS) in CAR T-cell Recipients.	Kevin McNerney/ Tania Jain/ Nikhil Vojjala/ Nausheen Ahmed
Non-Malignant Diseases	NM25-01	Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Diamond-Blackfan Anemia: A contemporary CIBMTR analysis.	Jane Koo/ Nicholas Gloude/ Nasheed Hossain/ Pashna Munshi/ Hemalatha Rangarajan/ Niketa C. Shah
Pediatric Cancer	PC25-01	Impact of Planned Post-Transplant Granulocyte Colony Stimulating Factor (G-CSF) on Transplant-Related Outcomes in Pediatric Patients with Malignant Disease Undergoing Haploidentical Hematopoietic Cell Transplant (HCT) with Post-Transplant Cyclophosphamide (ptCy) for Graft vs. Host Disease (GVHD) Prophylaxis.	Laurie Davis/ Prakash Satwani
Plasma Cell Disorders	MM25-01	Predictors of Early Relapse and Durable Remissions in patients with multiple myeloma treated with BCMA-Targeted CAR T-Cell Therapy	Alaa Ali/ Murali Janakiram/ Gurbakhash Kaur/ Haamza Hashmi/ Sham Mailankody/ Saad Z. Usmani
Plasma Cell Disorders	MM25-02	Outcomes of Out-of-specification BCMA-directed Chimeric antigen receptor (CAR) T-cell therapies in patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma.	Danai Dima/ Doris Hansen